FibroBiologics, Inc. Common Stock
FBLG · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.09 | -0.03 | -0.01 |
| FCF Yield | -16.91% | -17.46% | -16.11% | -4.56% |
| EV / EBITDA | -4.65 | -5.83 | -6.55 | -22.49 |
| Quality | ||||
| ROIC | -69.60% | -38.59% | -47.87% | -27.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.69 | 0.86 | 1.06 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 5.22% | 21.08% | -67.65% | -21.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.40 | -0.43 | 0.32 | 1.17 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -618.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |